Universiteit Leiden

nl en

Martin Houde

Postdoc

Name
Dr. M. Houde
Telephone
+31 71 527 6038
E-mail
m.houde@lacdr.leidenuniv.nl

Martin Houde obtained his PhD in Pharmacology from the Université de Sherbrooke, in Sherbrooke, Canada, in 2017. He received a Master’s scholarship from the Fonds de Recherche du Québec – Santé (FRQS), supporting his work on the inhibition mechanisms of platelet aggregation in atherosclerosis. His thesis focused of the role of chymase in the biosynthesis of endothelin-1, the progression of atherosclerosis and the prognosis of myocardial infarction in the mouse. His PhD work was supported initially by a FRQS doctoral award and then by the Frederick Banting & Charles Best Canadian doctoral research award from the Canadian Institutes for Health Research (CIHR). In 2017, he started working as a post-doctoral researcher in the group of Prof Dr Miranda van Eck, at the Leiden Academic Center for Drug Research in the Division of Biotherapeutics. His current research explores the role of mast cells and their proteases on macrophage lipid metabolism in the settings of atherosclerosis.

CARRIER, E.*, HOUDE, M.*, GRANDBOIS, M., BKAILY, G., WARNER, T.D., D’ORLÉANS-JUSTE, P. (2017). Inhibition of platelet aggregation ex vivo is repressed in apolipoprotein E deficient mice. Can J Physiol Pharmacol. 95(8):954-60.
*: co-first authorship.

HOUDE, M., DESBIENS, L., SCHWERTANI, A., PEJLER, G., IGLARZ, M., D’ORLÉANS-JUSTE, P. (2016). Endothelin receptor antagonist macitentan or deletion of mouse mast cell protease 4 delays lesion development in atherosclerotic mice. Life Sci, 159:71-5.

HOUDE, M., DESBIENS, L., D’ORLÉANS-JUSTE, P. (2016). Endothelin-1 synthesis, signalling and vasoreactivity. Adv Pharmacol, 77:143-75.

SEMAAN, W., DESBIENS, L., HOUDE, M., LABONTÉ, J., GAGNON, H., YAMAMOTO, D., TAKAI, S., LAIDLAW, T., BKAILY, G., SCHWERTANI, A., PEJLER, G., LÉVESQUE, C., DESJARDINS, R., DAY, R., D’ORLÉANS-JUSTE, P. (2015) Chymase inhibitor-sensitive synthesis of endothelin-1 (1-31) by recombinant mouse mast cell protease 4 and human chymase. Biochem Pharmacol. 94(2):91-100.

HOUDE, M., JAMAIN, M.D., LABONTÉ, J., DESBIENS, L., PEJLER, G., GURISH, M., TAKAI, S., D’ORLÉANS-JUSTE, P. (2013). Pivotal role of mouse mast cell protease 4 in the conversion and pressor properties of Big-endothelin-1. J Pharm Exp Ther. 346(1):31-7.

D’ORLÉANS-JUSTE, P., HOUDE, M., SEMAAN, W. (2013). Are sildenafil derivatives useful even in unborn males? Hypertension. 62(4):685-6.

BROCHU, I., HOUDE, M., DESBIENS, L., SIMARD, E., GOBEIL, F., SEMAAN, W., BKAILY, G., D’ORLÉANS-JUSTE, P. (2013). High salt-induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722. Br J Pharmacol. 170(2):266-77.

HOUDE, M., SEMAAN, W., RAE, G., D’ORLÉANS-JUSTE, P. (2012). GPCR models of pain in cardiovascular diseases: Contributions of kinins and endothelins. Drug Disc Today: Dis Models. 9(3):e137-42.

HOUDE, M., LABONTÉ, J., D’ORLÉANS-JUSTE, P. (2011). Peptide and non-peptide antagonists targeting endothelin receptors in physiology and pathology. Curr Pharm Des. 17(25):2613-25.

D’ORLÉANS-JUSTE, P., HOUDE, M., RAE, G.A., BKAILY, G., CARRIER, E., SIMARD, E. (2008). Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies.
Vascul Pharmacol. 49(2-3):51-62.

Postdoc

  • Wiskunde en Natuurwetenschappen
  • Leiden Academic Centre for Drug Research
  • LACDR/Biopharmaceutics

Work address

Gorlaeus Building
Einsteinweg 55
2333 CC Leiden
Room number EE1.13

Contact

Publications

No relevant ancillary activities

This website uses cookies. More information